Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: BoredMember who wrote (10298)	5/16/2018 4:24:58 AM
From: HardToFind	Respond to of 12873

Exactly right! These issues are now crystal clear. The communication from this company continues to amaze me. I could still use a bit more clarity on: how long they expect it will take to produce 750g of cGLP-compliant shingles drug material whether they have picked a lead candidate or intend to do formal tox studies on two drug compounds whether they intend to immediately pursue one herpes/shingles indication or three While I'm not amazed, I do appreciate the effort by Diwan to communicate.